WO2000016618A1 - Improved cryoprotectant solutions - Google Patents
Improved cryoprotectant solutions Download PDFInfo
- Publication number
- WO2000016618A1 WO2000016618A1 PCT/US1999/021736 US9921736W WO0016618A1 WO 2000016618 A1 WO2000016618 A1 WO 2000016618A1 US 9921736 W US9921736 W US 9921736W WO 0016618 A1 WO0016618 A1 WO 0016618A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- solution
- cryoprotectant
- solutions
- cryopreservation
- vitrification
- Prior art date
Links
- 239000002577 cryoprotective agent Substances 0.000 title claims abstract description 134
- 238000004017 vitrification Methods 0.000 claims abstract description 72
- 231100000419 toxicity Toxicity 0.000 claims abstract description 54
- 230000001988 toxicity Effects 0.000 claims abstract description 54
- 238000005138 cryopreservation Methods 0.000 claims abstract description 48
- 238000007710 freezing Methods 0.000 claims abstract description 43
- 230000008014 freezing Effects 0.000 claims abstract description 43
- 238000000034 method Methods 0.000 claims abstract description 43
- 239000000203 mixture Substances 0.000 claims abstract description 40
- 230000035899 viability Effects 0.000 claims abstract description 37
- 230000000149 penetrating effect Effects 0.000 claims abstract description 32
- 238000010792 warming Methods 0.000 claims abstract description 25
- 238000004031 devitrification Methods 0.000 claims abstract description 22
- 238000004781 supercooling Methods 0.000 claims abstract description 19
- 238000003860 storage Methods 0.000 claims abstract description 13
- 239000000243 solution Substances 0.000 claims description 315
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 184
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 claims description 146
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 100
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 38
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 38
- 210000004027 cell Anatomy 0.000 claims description 30
- 238000001816 cooling Methods 0.000 claims description 24
- 239000003795 chemical substances by application Substances 0.000 claims description 22
- 210000000056 organ Anatomy 0.000 claims description 20
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 18
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 18
- 210000001519 tissue Anatomy 0.000 claims description 17
- 150000001408 amides Chemical class 0.000 claims description 16
- 108010053481 Antifreeze Proteins Proteins 0.000 claims description 15
- 239000004202 carbamide Substances 0.000 claims description 15
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 15
- 239000000523 sample Substances 0.000 claims description 15
- 239000000126 substance Substances 0.000 claims description 15
- 210000003734 kidney Anatomy 0.000 claims description 12
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 12
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N Vilsmeier-Haack reagent Natural products CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 11
- 229920000642 polymer Polymers 0.000 claims description 11
- 229960004063 propylene glycol Drugs 0.000 claims description 11
- 235000013772 propylene glycol Nutrition 0.000 claims description 11
- 238000012360 testing method Methods 0.000 claims description 11
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 claims description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- 230000000959 cryoprotective effect Effects 0.000 claims description 8
- 239000007864 aqueous solution Substances 0.000 claims description 7
- 231100001231 less toxic Toxicity 0.000 claims description 7
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 6
- ROWKJAVDOGWPAT-UHFFFAOYSA-N Acetoin Chemical compound CC(O)C(C)=O ROWKJAVDOGWPAT-UHFFFAOYSA-N 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 230000009467 reduction Effects 0.000 claims description 6
- 239000013078 crystal Substances 0.000 claims description 5
- XLSMFKSTNGKWQX-UHFFFAOYSA-N hydroxyacetone Chemical compound CC(=O)CO XLSMFKSTNGKWQX-UHFFFAOYSA-N 0.000 claims description 5
- 229920001223 polyethylene glycol Polymers 0.000 claims description 5
- 238000010257 thawing Methods 0.000 claims description 5
- PSJBSUHYCGQTHZ-UHFFFAOYSA-N 3-Methoxy-1,2-propanediol Chemical compound COCC(O)CO PSJBSUHYCGQTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 239000003966 growth inhibitor Substances 0.000 claims description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 3
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 3
- 230000002528 anti-freeze Effects 0.000 claims description 3
- 210000000170 cell membrane Anatomy 0.000 claims description 3
- 239000013043 chemical agent Substances 0.000 claims description 3
- 230000009477 glass transition Effects 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- GFAZHVHNLUBROE-UHFFFAOYSA-N hydroxymethyl propionaldehyde Natural products CCC(=O)CO GFAZHVHNLUBROE-UHFFFAOYSA-N 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 239000012528 membrane Substances 0.000 claims description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 3
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 claims description 2
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- 238000003556 assay Methods 0.000 claims description 2
- 210000002257 embryonic structure Anatomy 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 231100000252 nontoxic Toxicity 0.000 claims description 2
- 230000003000 nontoxic effect Effects 0.000 claims description 2
- 229920000166 polytrimethylene carbonate Polymers 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 239000012472 biological sample Substances 0.000 claims 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims 3
- 230000000153 supplemental effect Effects 0.000 claims 3
- 239000004386 Erythritol Substances 0.000 claims 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims 2
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 claims 2
- ATHHXGZTWNVVOU-UHFFFAOYSA-N N-methylformamide Chemical compound CNC=O ATHHXGZTWNVVOU-UHFFFAOYSA-N 0.000 claims 2
- 239000012190 activator Substances 0.000 claims 2
- WERYXYBDKMZEQL-UHFFFAOYSA-N butane-1,4-diol Chemical compound OCCCCO WERYXYBDKMZEQL-UHFFFAOYSA-N 0.000 claims 2
- 230000001413 cellular effect Effects 0.000 claims 2
- 239000008150 cryoprotective solution Substances 0.000 claims 2
- 229960002887 deanol Drugs 0.000 claims 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims 2
- 229940009714 erythritol Drugs 0.000 claims 2
- 235000019414 erythritol Nutrition 0.000 claims 2
- 229920006158 high molecular weight polymer Polymers 0.000 claims 2
- 238000010348 incorporation Methods 0.000 claims 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 claims 2
- 229940035437 1,3-propanediol Drugs 0.000 claims 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 1
- 108010010803 Gelatin Proteins 0.000 claims 1
- 229920001612 Hydroxyethyl starch Polymers 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- VLCDUOXHFNUCKK-UHFFFAOYSA-N N,N'-Dimethylthiourea Chemical compound CNC(=S)NC VLCDUOXHFNUCKK-UHFFFAOYSA-N 0.000 claims 1
- OWBTYPJTUOEWEK-UHFFFAOYSA-N butane-2,3-diol Chemical compound CC(O)C(C)O OWBTYPJTUOEWEK-UHFFFAOYSA-N 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 235000014633 carbohydrates Nutrition 0.000 claims 1
- PMMYEEVYMWASQN-IMJSIDKUSA-N cis-4-Hydroxy-L-proline Chemical compound O[C@@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-IMJSIDKUSA-N 0.000 claims 1
- 229920001577 copolymer Polymers 0.000 claims 1
- RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 claims 1
- 238000010790 dilution Methods 0.000 claims 1
- 239000012895 dilution Substances 0.000 claims 1
- 229920000159 gelatin Polymers 0.000 claims 1
- 239000008273 gelatin Substances 0.000 claims 1
- 235000019322 gelatine Nutrition 0.000 claims 1
- 235000011852 gelatine desserts Nutrition 0.000 claims 1
- 229940050526 hydroxyethylstarch Drugs 0.000 claims 1
- MTMMGZCTRGFZAH-UHFFFAOYSA-N pent-1-ene-1,5-diol Chemical compound OCCCC=CO MTMMGZCTRGFZAH-UHFFFAOYSA-N 0.000 claims 1
- 229920001983 poloxamer Polymers 0.000 claims 1
- 229920002432 poly(vinyl methyl ether) polymer Polymers 0.000 claims 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 claims 1
- 108010000222 polyserine Proteins 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 58
- 230000001965 increasing effect Effects 0.000 abstract description 7
- 238000011084 recovery Methods 0.000 abstract description 7
- 230000002829 reductive effect Effects 0.000 abstract description 5
- 231100000048 toxicity data Toxicity 0.000 abstract description 5
- 230000000694 effects Effects 0.000 description 17
- 239000011734 sodium Substances 0.000 description 17
- 241000283973 Oryctolagus cuniculus Species 0.000 description 16
- 208000014674 injury Diseases 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 15
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 12
- 230000006378 damage Effects 0.000 description 12
- 238000007496 glass forming Methods 0.000 description 12
- 231100000331 toxic Toxicity 0.000 description 12
- 230000002588 toxic effect Effects 0.000 description 12
- 208000027418 Wounds and injury Diseases 0.000 description 10
- 238000004321 preservation Methods 0.000 description 10
- 230000001054 cortical effect Effects 0.000 description 8
- 239000011521 glass Substances 0.000 description 8
- 230000008018 melting Effects 0.000 description 8
- 238000002844 melting Methods 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 210000004087 cornea Anatomy 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 230000008733 trauma Effects 0.000 description 6
- 238000013459 approach Methods 0.000 description 5
- 210000003494 hepatocyte Anatomy 0.000 description 5
- 231100000053 low toxicity Toxicity 0.000 description 5
- 230000006911 nucleation Effects 0.000 description 5
- 238000010899 nucleation Methods 0.000 description 5
- 101100419062 Caenorhabditis elegans rps-2 gene Proteins 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000002981 blocking agent Substances 0.000 description 4
- 229960001330 hydroxycarbamide Drugs 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 238000006386 neutralization reaction Methods 0.000 description 4
- 229920003081 Povidone K 30 Polymers 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000001045 blue dye Substances 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000010432 diamond Substances 0.000 description 2
- BTVWZWFKMIUSGS-UHFFFAOYSA-N dimethylethyleneglycol Natural products CC(C)(O)CO BTVWZWFKMIUSGS-UHFFFAOYSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000011067 equilibration Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 2
- 239000006193 liquid solution Substances 0.000 description 2
- 238000013059 nephrectomy Methods 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- SNZAEUWCEHDROX-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-one;trihydrate Chemical compound O.O.O.FC(F)(F)C(=O)C(F)(F)F SNZAEUWCEHDROX-UHFFFAOYSA-N 0.000 description 1
- XYVDMXOXWWUIKN-UHFFFAOYSA-N 1-methoxypropane-1,2,3-triol Chemical compound COC(O)C(O)CO XYVDMXOXWWUIKN-UHFFFAOYSA-N 0.000 description 1
- 101710123134 Ice-binding protein Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229920001807 Urea-formaldehyde Polymers 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000002821 anti-nucleating effect Effects 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 230000008238 biochemical pathway Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 238000001342 constant potential amperometry Methods 0.000 description 1
- 210000000399 corneal endothelial cell Anatomy 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- -1 dihγdroxγacetone Chemical compound 0.000 description 1
- AFABGHUZZDYHJO-UHFFFAOYSA-N dimethyl butane Natural products CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000002194 freeze distillation Methods 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 230000006910 ice nucleation Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 1
- 231100000324 minimal toxicity Toxicity 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000000082 organ preservation Substances 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 210000002220 organoid Anatomy 0.000 description 1
- 239000002357 osmotic agent Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000000063 preceeding effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000012950 reanalysis Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
- A01N37/02—Saturated carboxylic acids or thio analogues thereof; Derivatives thereof
-
- A01N1/02—
-
- A01N1/0221—
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N31/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic oxygen or sulfur compounds
- A01N31/02—Acyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K3/00—Materials not provided for elsewhere
- C09K3/18—Materials not provided for elsewhere for application to surfaces to minimize adherence of ice, mist or water thereto; Thawing or antifreeze materials for application to surfaces
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K3/00—Materials not provided for elsewhere
- C09K3/18—Materials not provided for elsewhere for application to surfaces to minimize adherence of ice, mist or water thereto; Thawing or antifreeze materials for application to surfaces
- C09K3/185—Thawing materials
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K5/00—Heat-transfer, heat-exchange or heat-storage materials, e.g. refrigerants; Materials for the production of heat or cold by chemical reactions other than by combustion
- C09K5/20—Antifreeze additives therefor, e.g. for radiator liquids
Definitions
- the invention relates generally to the field of cryobiology. More specifically, the invention relates to method of cryoprotection and novel cryoprotectant solutions and the principles that allow minimization of their toxicity, preferably without substantially weakening their ability to vitrify and to resist devitrification.
- Cryopreservation refers to the preservation of systems containing living cells at temperatures below the normal freezing point of water (O ⁇ C).
- the history and literature of cryobiology the field of science that attempts to understand low temperature biological phenomena and to improve methods of cryopreservation, is large and voluminous, and its successes have touched hundreds of millions of Americans and many others around the world in one way or another over the past 40 years or so. But despite its many spectacular successes, cryobiology has still not found ways to cryopreserve transplantable kidneys, hearts, and livers (despite the high value such technology would have) or even many simpler systems, for unlimited times. In many cases, cells such as human and bull sperm and even human corneas can withstand freezing, but with undesirable amounts of injury.
- cryoprotectant . . .
- all ice formation could be suppressed completely by using a concentration of cryoprotectant sufficient to ensure vitrification. Fahy, Cryobiology 23:1 -13 (1986).
- Fahy himself has described numerous efforts to improve his own vitrification solutions for tissue slices and organs, without progress since the adoption of the VS4-VS41 A series around 1986 (Fahy, Levy, and Ali, Cryobiology 24: 196213, 1987; Fahy, Lilley, Linsdell, Douglas, and Meryman, Cryobiology 27: 247268, 1990; Fahy, Cryobiology 35: 344-345, 1997).
- the present application provides cryoprotectant solutions having unprecedented non-toxicity even at higher total concentrations than have previously been contemplated, and while retaining good stability on warming and methods for designing additional examples thereof.
- the user has great flexibility in choosing variations for fine-tuning for the user's particular needs.
- the invention permits the design of entirely new cryoprotective substances in keeping with the new design principles disclosed herein. The inventors believe this new cryopreservation technology will allow successful preservation of most systems by freezing or by vitrification, especially since it consists not only of specific compositions but also involves several new general principles in cryobiology.
- the present invention also introduces novel cryoprotectants identified for specific uses based on the general principles and novel uses of previously known cryoprotectants.
- the invention provides new theoretical and practical guidelines useful for creating minimum-toxicity vitrification solutions.
- the invention also provides specific families of vitrification solutions based on these new theoretical insights that have minimum toxicity and that are effective for dissimilar biological systems.
- Another aspect of the present invention provides improved solutions for cryopreservation of cells, tissues, organs, artificial organs, artificial tissues, and non-living biological systems.
- the invention also provides specific families of freezing solutions based on the new vitrification solutions.
- the invention provides cryoprotectant solutions and methods that also have applications in preservation by freezing point depression, supercooling, and cold storage.
- the invention also provides specific solutes and combinations of solutes that, when used in the proper way, have wholly unforeseen beneficial effects (reduced cryoprotectant toxicity, enhanced vitrification tendency, and enhanced resistance to devitrification). New ways of, and new agents for, inhibiting the growth of ice crystals in aqueous solutions and in other contexts are described herein.
- the invention provides methods for scaling up the vitrification of small biological systems for use on large biological systems with minimal or no required increases in the concentrations of standard cryoprotectants.
- the invention further provides cryoprotectant solutions that, very surprisingly, have no gap between the concentration that vitrifies and the concentration that can be warmed at modest rates without devitrification.
- Figure 1 shows the toxicities (measured by reductions in tissue K+/Na + ratio) of 13 vitrification solutions for rabbit renal cortical slices.
- Figure 2 represents the toxicity data of Figure 1 in relation to the water content of the solution.
- Figure 3 shows a retrospective analysis of viability data in terms of qv * .
- Figure 4 shows the viability of rabbit renal cortical slices plotted against qv* in solutions containing a mixture of dimethyl sulfoxide (DMSO), formamide, and ethylene glycol (EG).
- DMSO dimethyl sulfoxide
- EG ethylene glycol
- Figure 5 shows the data of Figure 3 plotted in terms of the absolute concentrations of DMSO, formamide, and ethylene glycol in the solutions, as well as in relation to the mole percentage of D(1)F in the mixture.
- Figure 6 shows the effect of varying Veg by a) increasing the D(1 )F:EG mole ratio and by b) systematically replacing EG with PG.
- Figure 7 shows the effect of varying Veg by reducing formamide in favor of DMSO or in favor of ethylene glycol, or by reducing DMSO in favor of ethylene glycol.
- Figure 8 describes the universality of formamide, urea, formamide/urea mixtures, and hydroxyurea in terms of their effects on cell viability and in terms of the neutralization of these effects by dimethyl sulfoxide.
- Figure 9 illustrates the process for selecting solutions for use in supercooling experiments on living systems.
- Figure 10 summarizes the gain in stability and the gain in viability attained by the new solutions in comparison to the former standard solution, VS41 A.
- One aspect of the present invention relates to a broad family of rationally-composed and balanced cryoprotectant mixtures that provide minimum-toxicity compositions for the cryopreservation of proteins, organelles, cell extracts, cells, tissues, blood vessels, organs, and artificial or engineered cells, tissues, blood vessels, organs or organoids, organisms, or other biological systems by vitrification, freezing, and other means, and the associated principles that govern the rational formulation of superior cryoprotectant solutions. It is believed that the present invention will allow the practitioner of ordinary skill in the art to select a cryopreservation solution for use that will surpass the value of his or her prior cryopreservation solution.
- Vitrification solutions developed by others sometimes give recoveries of 80% or more, but this is deceptive. All of these solutions require rapid addition and removal of the cryoprotectant, and typically involve exposure to the vitrifiable solution for around two minutes or less. The effect of this minimal-exposure regimen is to mask the otherwise severe intrinsic toxicity of these solutions, but such brief exposure constraints limit the use of such vitrification solutions to small samples.
- cryoprotectant solutions that can be in contact with cells for relatively long times (circa, 40 minutes) at their peak concentrations, and so the solutions must be intrinsically less toxic.
- cryoprotectant solutions There is no current ability to predict with confidence which cryoprotectant solutions will be effective and which will be ineffective for any unfamiliar living system, and there is no method other than random experimentation and guessing for deriving more promising formulae to test. This has greatly limited work on developing cryoprotectant solutions. It has also given the entire field a lack of direction and has resulted in a prevailing state of confusion that has prevented rapid advances.
- the first step to choosing minimum-toxicity solutions for cryopreservation is to choose agents that vitrify aqueous solutions "poorly,” meaning that relatively high concentrations of cryoprotectant water bonding sites are required relative to water to prevent ice formation. This means that these solutions contain relatively little water compared to more strongly glass-forming solutions. This should make such solutions more toxic according to the traditional wisdom in the field of cryobiology, and is counterintuitive given that cells require water for stabilizing delicate cell proteins and membranes. Nevertheless, we show herein for the first time that the opposite is true, i.e., that these are the best solutions, not the worst solutions as commonly believed, for avoiding toxicity.
- cryoprotectant solutions may optionally include polymeric materials of about 1 ,000 daltons to 50,000 daltons in relative molecular mass in place of variable amounts of penetrating cryoprotectant so as to permit a reduction in intracellular cryoprotectant concentration and, thereby, an effective further increase in intracellular water availability.
- These polymers may or may not include polymers capable of specifically blocking ice nucleation or ice growth.
- the solutions may also contain low molecular mass agents (less than 1,000 daltons in relative molecular mass) that are able to specifically inhibit the nucleation and/or growth of ice.
- npCPAs to enhance vitrification is routine, however, our addition of the use of npCPAs in combination with weakly glass-forming cryoprotectant combinations is not. We also added the use of relatively low molecular mass npCPAs as taught here for the first time. Lastly, the combination of relatively low molecular mass npCPAs and weakly glass-forming cryoprotectant mixtures is new. Finally, the combination of all modalities (weak glass-formers, npCPAs or low mass npCPAs (ImnpCPAs), and ice blocking agents) is still more remote from the prior art.
- the qv * method for identifying useful cryoprotectant solutions based on this concentration scale is: to select at least one cryoprotectant whose qv* is below 2.0, include it in a mixture with other cryoprotectants, determine the Cv of the resulting mixture in the normal way (see, for example, Fahy et al, Cryobiology 21 : 407- 426, 1984), calculate q * at Cv (qv * ) (note: the number of moles of water can be readily determined from the weight of a given volume of solution minus the number of grams of all solutes, i.e., from the number of grams of water per unit volume or per unit weight), compare the resulting qv * value to the qv * values of alternative cryoprotectant solutions, and selecting lower qv* value solutions in general preference to higher qv * solutions, qv * values can be estimated adequately from published Q values by estimating that the densities of all solution components as pure substances are unchanged by being in solution with other substances (the validity of a
- a variant on this method is to determine q * at the concentration giving acceptable and consistent rates of devitrification, and base comparisons on this q* (qd * ).
- qa * which can be determined when cells are frozen to the same temperature
- rank the resulting freezing injury on the basis of the qa* values This will allow superior freezing solutions to be developed.
- qa* can also be used to select candidate solutions for preservation by freezing point depression at a given temperature, since, again, solutions having the same freezing point have the same water activity, providing a meaningful basis for comparison of q * values between different solutions.
- Another variant on the method is to select solutions for supercooling based on the q* values for solutions that are just concentrated enough to permit the desired degree of supercooling (qs*).
- the q * method will allow superior preservation by vitrification, freezing, freezing point depression, and supercooling. Further, solutions found for these applications may also be applied in low concentrations (below about 4 molar) to stabilize cells, tissues, and organs at temperatures above their equilibrium freezing/melting points (Tm) to prolong liquid state storage at these temperatures (cold storage).
- PVA polyvinyl alcohol
- cryopreservation solution formulation combine to provide a truly powerful capability for avoiding injury during and after cryo- or cold preservation, with expected broad practical and commercial utility.
- q * is the number of moles of water in a cryoprotectant solution per mole of polar groups present on penetrating cryoprotectants in the solution.
- qa* is q* for solutions at a standard water activity (generally established by freezing to a standard temperature).
- qd* is q* for solutions that exhibit a standard devitrification tendency.
- qs* is q * for solutions that exhibit a standard supercooling tendency in the presence of a standard amount of a nucleation inhibitor or ice crystal growth inhibitor, such as PVA for nucleation inhibition and antifreeze protein for crystal growth inhibition or thermal hysteresis induction.
- Cv is the concentration needed to vitrify 5-10 ml of solution at a cooling rate of about l OoC/min.
- “Vitrification” is defined to mean the solidification of a liquid solution as a glass rather than by freezing.
- Glass is defined herein to mean a liquid solution whose molecular motions have been virtually arrested by cooling to below the glass transition temperature of the solution.
- cryoprotectants are chemicals that reduce damage associated with cryopreservation. We recognize penetrating cryoprotectant(s) (pCPAs) as cryoprotectants that cross the cell membrane on a reasonable time scale (seconds to tens of minutes). Nonpenetrating cryoprotectant(s) (npCPAs) remain extracellular under most practical conditions.
- “Cryopreservation” is preservation of biological systems by freezing, vitrification, supercooling, or freezing point depression.
- Supercooling is cooling to a temperature below the equilibrium melting point, but above the glass transition temperature, without actually freezing the sample.
- cryoprotectant to reduce the melting point of an aqueous solution to below OoC, and to store a biological system (for example, a protein or an organ) within about plus or minus 3 degrees of that melting point, but below OoC.
- Cold storage refers to storage above the melting point of the solution, typically at OoC or above but in the presence of a cryoprotectant or cryoprotectant mixture used to stabilize the biological system.
- Ice blocking agents are chemicals that reduce or eliminate ice formation particularly well during cooling, warming, or isothermal holding, either by bonding directly to ice at the ice-liquid interface or by preventing nucleation, or by other means.
- Thermal hysteresis is or refers to the difference between the melting point of the solution and the temperature at which ice can grow at appreciable rates during cooling below this temperature. It has been shown that when a-axis-bonding ice blockers are present, ice growth is prevented or greatly inhibited despite the presence of ice below the melting point, until the low temperature limit for this effect is reached, which defines the magnitude of the thermal hysteresis in that case.
- Antifreeze proteins or AFPs, also called “thermal hysteresis proteins” or THPs
- THPs thermo hysteresis proteins
- VS41 A is a cryoprotectant solution known in the art and containing dimethyl sulfoxide, formamide, and 1,2- propanediol (propylene glycol, or PG) such that the total concentration of these three cryoprotectants is 55% w/v, the molar concentration of dimethyl sulfoxide equals the molar concentration of formamide, and the concentration of PG is 16.84% w/v.
- VS41 A is considered to be the least toxic vitrification solution known for mammalian organs.
- VS4 is a diluted version of VS41 A containing 6% w/v less penetrating cryoprotectant than VS41A and that can be vitrified using an applied pressure of 1,000 atmospheres.
- a “carrier” or “vehicle” solution is the portion of a cryoprotectant solution other than the cryoprotectants that are present in the solution; the “carrier” or “vehicle” solution is generally also used in the absence of cryoprotectants to support the viability of cells, organs, or tissues outside of the body. The invention will be described in greater detail below.
- cryoprotectant solutions contain three interacting parts: 1) penetrating cryoprotectant(s) (pCPAs), 2) nonpenetrating cryoprotectant(s) (npCPAs), and 3) high or low-molecular weight specific ice-blocking cryoprotectant(s) (ibCPAs).
- pCPAs penetrating cryoprotectant(s)
- npCPAs nonpenetrating cryoprotectant(s)
- ibCPAs high or low-molecular weight specific ice-blocking cryoprotectant(s)
- polyvinyl alcohol for inhibition of ice growth
- Reference to "polyvinyl alcohol” or “PVA” herein is intended to represent all forms of polyvinyl alcohol identified as being potentially useful in this companion application.
- polyvinyl alcohol and related compounds were found to inhibit the freezing of water and water solutions. These synthetic compounds preferentially bind and inhibit ice nucleating surfaces in a manner similar to natural antifreeze proteins. The resulting inhibition allows water and water solutions to supercool without ice formation to temperatures below the thermodynamic freezing point. The freezing inhibition occurs at concentrations as small as one part per million, although concentrations up to one part per hundred are preferred.
- the related compounds include any compounds with the formula [-CR 2 CR0H-] meaning where R is any atom, or group of atoms, except a hydroxyl group, and n > 3. In addition one or more of the hydroxyl groups can be replaced with chemical groups such as methoxyl, alkoxyl, and amine groups.
- the polyvinyl alcohol compounds preferably have a MW less than 1000 kDa, more preferably less then 10 kDa and even more preferably 130- 2000 daltons.
- the polyvinyl alcohol compounds preferably contain 1 to 25 mole percent vinyl acetate, more preferably 10-20 mole percent vinyl acetate and they can be atactic or syndiotactic.
- pCPA and npCPA mixtures are highly useful without ice-blocking substances, but require the use of ice-blocking substances in many best-mode solutions.
- ideal solutions for cryoprotection involve the use of all three elements of the invention in combination with one another, and less best mode but still excellent solutions can be obtained by using just one or two of these principles.
- corneas are believed to be impermeable to polymers such as PVA, and require pCPAs with or without additional non-ice-blocking npCPAs or the use of ice-blocking npCPAs primarily as osmotic agents.
- cryoprotectants or cryoprotectant mixtures should be chosen that are poor vitrifiers. This is the exact opposite of the standard approach to developing good solutions for vitrification of living systems. It is still true that, for a given cryoprotectant or mixture, one should not use a higher concentration than is needed for vitrification, since this will reduce, not increase water availability. But given a choice between two solutions that vitrify at different concentrations, the solution that vitrifies at a higher concentration will tend to have less toxicity than the other solution, provided other factors do not come into play.
- formamide is highly toxic compared to most cryoprotectants, but its toxicity can be fully neutralized by the addition of dimethyl sulfoxide (Fahy, da Mouta, Tsonev, Khirabadi, Mehl, and Meryman, in: Cell Biology of Trauma, JJ Lemasters and C Oliver, eds., CRC Press, 1995, pp. 333-356).
- cryoprotectants some living systems are particularly sensitive to specific cryoprotectants, one example being the sensitivity of the kidney to glycerol, which is a poor glass former but is both rather poorly penetrating and capable of directly entering into biochemical pathways to produce biochemical disturbances (for example, see Burch et al., J Biol Chem 245: 2092-2102, 1970, and Jans and Willem, Eur J Biochem 174: 67-73, 1988).
- Another factor that could come into play is reduction of the water content below a minimum value required for adequate hydration of biomolecules even in the presence of weak water-cryoprotectant interactions: presumably, there is an upper limit beyond which weak glass-forming ability becomes detrimental rather than beneficial.
- the Examples show that even very low qv* solutions (qv * ⁇ 1.6) have low toxicity.
- Example 1 Prediction of Toxicity using qv*: Solutions that Vitrify at 1000 Atmospheres in the
- Figures 1 and 2 display a reanalysis (performed in early July of 1998) of public information (Fahy, Levy, and Ali, Cryobiology 24: 196213, 1987) on the toxicity of several vitrification solutions of known composition.
- vitrification solutions will vitrify at 1,000 atmospheres and contain either 6% polyvinyl pyrrolidone of relative molecular mass 40 kDa [PVP K30] or 6% polyethylene glycol [PEG 8000].
- the data set is advantageous because all solutions analyzed are vitrifiable, the data set has low standard errors, and toxicity was convincingly dissociated from osmotic factors (see Fahy, Levy, and Ali, 1987, for discussion).
- viability was defined by the ratio of primarily intracellular potassium to intracellular sodium (K/Na ratio) after cryoprotectant washout and active metabolism for 90 min at the optimum temperature of 25°C.
- the test system was rabbit renal cortical slices.
- the toxicities are related to the total concentrations of the penetrating cryoprotective agents (pCPAs) needed for the solutions to vitrify (Cv).
- Cv was measured at 1 ,000 atmospheres of pressure and in the presence of 6% w/v PEG or PVP and is expressed in percent w/v, mole fraction, and molal units.
- Figure 2 represents the toxicity data of Figure 1 in relation to the water content of the solution, the number of moles of water in the solution per mole of pCPA in the solution, and the number of moles of water per mole of hydrogen-bonding groups that are present on the penetrating cryoprotectants in the solution (qv * ).
- Figure 3 shows two curves displaying the results of two separate experiments. It shows a retrospective analysis of viability data in terms of qv * , showing a) a good correlation between viability and qv * for solutions very different from those in Figure 2, and b) an elevation of viability when qv* is increased using polyvinyl alcohol to inhibit nucleation.
- Points 1-5 were done in a EuroCollins vehicle solution and consisted of a systematic variation in the proportion of EG:3-methoxy-1,2-propanediol or 2-methoxyethanol in comparison to VS41 A, whereas points 6-10 represent experiments carried out in the presence of a vehicle solution called GHP-2 with (points 8-10) or without (points 6 and 7) 1 % PVA of about a 7,000 dalton average molecular mass.
- GHP-2 vehicle solution
- points 6 and 7 1 % PVA of about a 7,000 dalton average molecular mass.
- Points 8-10 illustrate the fact that biological systems survive better when they are more fully hydrated despite being vitrifiable, thanks to the antinucleation abilities of PVA, which permit the amount of penetrating CPA to be reduced without preventing vitrification.
- Point 8 consists of VS4 (see below) rendered vitrifiable by the inclusion of 5% PVP at Mr 5000 plus 1 % PVA at Mr 7000 daltons.
- Table 1 recapitulates the six nominally weakest glass-forming solutes described in the most recently- published compendium of glass-forming compounds provided by Fahy (Fahy, in: Low Temperature Biotechnology: Emerging Applications and Engineering Contributions, JJ McGrath and KR Diller, eds, ASME, 1988, pp. 1 13146). Toxicity data is limited for these solutes, but at least two such solutes have been evaluated adequately. Acetamide, which is the weakest glass former in Table 1 based
- qv * should be the least toxic cryoprotectant of these six.
- 50% w/v acetamide is essentially non-toxic to kidney slices (Fahy, da Mouta, et al., in: Cell Biology of Trauma, C Oliver and JJ Lemasters, eds, 1995), which is probably a record and is in marked contrast to the toxicity of 50% DMSO or 50% 1,2-propanediol.
- Other weak glass-formers of interest include acetoin [Cv > " 60% w/w in water], hydroxyacetone, hexafluoroacetone trihydrate, and related molecules.
- formamide also has specific toxicity that must be neutralized by the simultaneous presence of dimethyl sulfoxide (Fahy, da Mouta, et al., in: Cell Biology of Trauma, C Oliver and JJ Lemasters, eds, 1995), limiting how high the formamide concentration and the formamide to dimethyl sulfoxide (F:D) ratio can be.
- the solutions were at the total concentration needed to vitrify in each case; no polymer was present.
- the toxicity of EG-D(1)F mixtures was once more consistent with the ranking of these mixtures according to qv * .
- Figure 5 indicates that the limit for an acceptable mole fraction of D(1)F/(D(1)F+ EG) is below 0.8 and above 0.67 for a total concentration of 57-58% w/v D(1)F, and that a concentration of about 14% formamide is the maximum that is associated with minimal injury.
- Example 5 Viability Correlates with q* in Modified VS41A
- VS41A was the best solution previously known to us, so it was of interest to compare it to solutions of lower qv * .
- VS41 A contains about 38.2% w/v D(1 )F, or almost exactly 14% formamide, the maximum amount found compatible with high viability in Example 4.
- the other component of VS41 A is 1 ,2-propanediol (PG), which is an excellent glass former (qv* about 2.6), and is a far better glass former than D(1)F, which is why it has been a major component of VS41A and predecessor solutions to it since about 1983. But according to the new theory, this component should be replaced, as much as possible, with a weaker glass-forming component.
- Ethylene glycol was therefore selected as a known weak glass-forming agent, and the PG in VS41A was replaced gram for gram with EG (forming a solution named Veg) to gain a further evaluation of the theory. Even though this modification was expected to lower the Cv of the solution, all attempted one-to-one replacement experiments in the past have failed to attain reductions in toxicity (see, e.g., Fahy, Cryobiology 35: 344-345, 1997). In the current test, however, this rule was broken, as indicated in Table 2.
- Toxicities of vitrification solutions can best be compared based on q * at the q * needed to vitrify, or qv*
- Table 2 The results shown in Table 2 were surprising and informative in several respects. In the first sense, they allowed the specific contribution of the PG in VS41 A to be identified as the cause of nearly three-quarters of the toxicity of VS41A. Second, they showed that a solution that is more concentrated than VS41A (on a molar basis) can have only about one-fourth the toxicity of VS41A (about a 10% vs. about a 60% reduction in K/Na ratio).
- Figure 6 presents a map of how the balance between EG, D(1 )F, and PG affects the viability of rabbit renal cortical slices when total concentration is held fixed at 55% w/v. It shows the effect of varying Veg by a) increasing the D(1)F:EG mole ratio and by b) systematically replacing EG with PG. The numbers within the points indicate the percent of untreated control K/Na ratio achieved after exposure to the composition defined by the ternary composition triangle (percent of control calculated without correction for background K/Na > 0).
- Figure 6 also shows that a D(1)F:EG mol % of up to 77 is feasible without a loss of viability. This is consistent with but further defines the result provided in Figure 5B.
- Figure 7 shows the effect of varying Veg by reducing formamide in favor of DMSO or in favor of ethylene glycol, or by reducing DMSO in favor of ethylene glycol, indicating that variations within these limits maintain Veg in a range of high viability.
- Figure 7 is in the same format as Figure 6, except that no PG is involved and variations in the D:F ratio are included. The point yielding 90.6-103% of control function represents
- Veg. Veg was varied in three directions: formamide was progressively replaced with DMSO (line descending to the right); formamide was progressively replaced with EG (line descending to the left); and DMSO was lowered in favor of EG (line proceeding horizontally to the left).
- all three variations tended to worsen the K/Na ratio, implying that the formula for Veg is nearly optimum, but all of the variant data points remain far superior to VS41A, and hence all are acceptable variants within the scope of the invention.
- raising formamide is expected to result in increased injury, so the only other possibility for improving the formula for Veg (other than by including other agents) is to increase the amount of DMSO in the solution at the expense of ethylene glycol. Information bearing on this question is given below.
- Figure 8 collects data on the toxic effect of amides and amide mixtures on rabbit renal cortex and the reversal of these toxic effects by DMSO. It describes the universality of formamide, urea, formamide/urea mixtures, and hydroxyurea in terms of their effects on cell viability and in terms of the neutralization of these effects by dimethyl sulfoxide. These data extend prior data (Fahy, da Mouta, Tsonev, Khirabadi, Mehl, and Meryman, in: Cell Biology of Trauma, JJ Lemasters and C Oliver, eds., CRC Press, 1995, pp. 333-356) to a surprising degree, as follows.
- hydroxyurea, urea, and equal weights of urea and formamide appear to have the same toxic effect as formamide alone on a percent weight/volume basis. This is true despite variations in molecular mass between these amides, despite the fact that urea and hydroxyurea have two amino groups vs. the one amino group of formamide, and despite the fact that one of the amino groups of hydroxyurea is modified with a hydroxyl group.
- urea Like formamide, there may be an upper limit on the amount of urea or other amide whose toxicity can be reversed by DMSO.
- a urea concentration in the vicinity of 15% should be essentially fully detoxifiable, and may have advantages, because urea forms even more poorly glass-forming solutions than does formamide (point 6 of Figure 3).
- urea-rich solutions vitrify, they fail to devitrify on warming, a remarkable and unexpected property presumably due to depletion of water from the solution to such an extent that insufficient water remains to freeze.
- Advantageous compositions containing of urea are given in and implied by the master vitrification solution table (see below).
- Figure 9 illustrates the process for selecting solutions for use in supercooling experiments on living systems.
- Figure 9 graphically depicts the concentrations of Veg solutes needed, in the absence and in the presence of 0.1 -1.0% PVA of molecular mass " 1,000 daltons (a forthcoming commercial product called "X- 1000"), to establish stable supercooling for at least 48 hours in a household refrigerator freezer compartment, the most practically-available temperature for supercooled storage.
- the circles represent solutions containing the physiological solution RPS-2, which is described in the literature, and squares represent solutions based on a vehicle called RPS-T, wherein 175 mM trehalose plus 5 mM glucose replace the 180 mM glucose concentration found in RPS-2.
- Table 3 Carrier (Vehicle) Solutions Used in These Studies
- 1 % X-1000 extends the range of accessible concentrations for short term storage (for example, for 48 hr) in low-toxicity media from the initial 5- 6°C to a total concentration depression of 10°C, or about double the normal margin.
- one method for storing systems in low-toxicity media under conditions of supercooling is to a) determine the desired storate temperature, b) determine the concentration of cryoprotectant that has that temperature as its equilibrium melting point, c) subtract about 8-10% w/v from that equilibrium concentration, and d) store the system of interest at the storage temperature of interest in the thus-calculated solution of interest.
- higher concentrations of PVA can be used for still greater supercooling protection.
- One caution is that it is essential to ensure full permeation of the PVA into the sample prior to cooling, and agitation of the sample should be minimized during storage. In preliminary experiments, some test tissue slices froze due to incomplete penetration of PVA into the inadequately exposed slices.
- a recent freezing experiment compared freezing of rabbit kidney slices to -130°C in the presence of either 30% w/v DMSO or 30% w/v Veg solutes.
- the K/Na ratio after freezing and thawing in DMSO was 2.46 + /- 0.30, whereas the K/Na ratio after freezing and thawing in 30% w/v Veg solutes was 3.10 +/- 0.07 (p ⁇ 0.05).
- a recent freezing experiment compared freezing of rat hepatocytes in suspension to -140oC in the presence of either 10% v/v DMSO or 10% v/v Veg solutes.
- Example 12 Veg-T ⁇ pe Vitrification Solutions are Less Toxic to Human Corneas than is VS41A
- Example 13 VS41 A is Superior to Prior Art Vitrification Solutions, but Veg is Superior to VS41A
- EFS 40% v/v EG + 18% Ficol (70kD) + 0.3 M sucrose
- EGP 8.5 M EG + 10%
- PVP 40% v/v EG + 20% PVP + 11.3% trehalose
- Example 14 Many Variations of Veg are Superior to VS41A Table 6, which follows, lists solutions found to be advantageous within the present invention. The listing includes the identity of the solution, the viability result associated with the solution in relation to exposure to other solutions or in relation to untreated controls, and information concerning the vitrification tendency and devitrification tendency of the solution. Further variations will be apparent to those of skill in the art upon contemplation of the exemplary solutions listed.
- V52 is a composition halfway between VS4 and VS41A, and has been used to perfuse rabbit kidneys to the point of osmotic equilibration, cool them to -35°C, warm them back up, and recover them after transplantation with immediate contralateral nephrectomy with attainment of a 100% survival rate and a 100% return of the recipient rabbits to a permanently normal clinical state (Khirabadi et al., 1995).
- Veg + 3%EG can achieve the same result in terms of toxicity, it may then be sufficiently stable to go on to successfully bank these kidneys at cryogenic temperatures by vitrification. And Veg + 3% EG is far from the most superior or advantageous solution listed in Table 5. It should be clear from this perspective that even apparently small gains in toxicity can be crucial to the success of a cryopreservation process, and that solutions ranked at least as low as solution 15- 1 could be of great value.
- FIG. 10 Additional perspective is provided in Figure 10, in which the data of Table 6 are converted into a rough estimate of the viability vs. critical warming rate curve to prevent serious devitrification on warming.
- VS41A open boxes
- Solutions of the invention at the same estimated critical heating rate, provide about double the viability permitted by VS41A (vertical arrow near "VS41 A" label).
- the solutions of the invention can provide the same viability but at a critical warming rate about 100 times lower than the critical rate needed for VS41A.
- the experimental variability of the data is suggested by the diamonds, which depict two independent tests (34-4 and
- Samples were tested by affixing at least one test tube containing 5 ml of sample plus 1 ml of isopentane as a surface layer to a rigid support and attaching this support a fixed distance over the surface of liquid nitrogen in a medium-necked dewar, with one parallel sample of the same solution being run concurrently to document the thermal history of the sample, and were scored based upon their appearance after cooling or based upon their solubility. The scores were considered reliable only for the samples not containing thermocouple probes. All samples contained a biologically compatible vehicle or carrier solution. After cooling and scoring were complete, samples were also examined where applicable for stability on warming. This was accomplished by transferring the sample and reference tubes into either a) a bath of approx.
- E or EG Ethylene glycol
- D DMSO
- F formamide
- D(n)Y DMSO in an n:1
Landscapes
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Combustion & Propulsion (AREA)
- Materials Engineering (AREA)
- Organic Chemistry (AREA)
- Dentistry (AREA)
- Zoology (AREA)
- Plant Pathology (AREA)
- Health & Medical Sciences (AREA)
- Agronomy & Crop Science (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Pest Control & Pesticides (AREA)
- Environmental Sciences (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Thermal Sciences (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Materials Applied To Surfaces To Minimize Adherence Of Mist Or Water (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU10939/00A AU1093900A (en) | 1998-09-21 | 1999-09-21 | Improved cryoprotectant solutions |
CA2345009A CA2345009C (en) | 1998-09-21 | 1999-09-21 | Improved cryoprotectant solutions |
AT99954636T ATE313259T1 (en) | 1998-09-21 | 1999-09-21 | IMPROVED COLD PROTECTION SOLUTIONS |
EP99954636A EP1115281B9 (en) | 1998-09-21 | 1999-09-21 | Improved cryoprotectant solutions |
DE69929071T DE69929071T2 (en) | 1998-09-21 | 1999-09-21 | IMPROVED COOLING PROTECTION SOLUTIONS |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10119498P | 1998-09-21 | 1998-09-21 | |
US60/101,194 | 1998-09-21 | ||
US12715899P | 1999-03-31 | 1999-03-31 | |
US60/127,158 | 1999-03-31 | ||
US12814299P | 1999-04-07 | 1999-04-07 | |
US60/128,142 | 1999-04-07 | ||
US14358799P | 1999-07-13 | 1999-07-13 | |
US60/143,587 | 1999-07-13 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000016618A1 true WO2000016618A1 (en) | 2000-03-30 |
WO2000016618A9 WO2000016618A9 (en) | 2000-08-24 |
Family
ID=27493184
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/021736 WO2000016618A1 (en) | 1998-09-21 | 1999-09-21 | Improved cryoprotectant solutions |
PCT/US1999/021967 WO2000016619A1 (en) | 1998-09-21 | 1999-09-21 | Polyvinyl alcohol compounds for inhibition of ice growth |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/021967 WO2000016619A1 (en) | 1998-09-21 | 1999-09-21 | Polyvinyl alcohol compounds for inhibition of ice growth |
Country Status (7)
Country | Link |
---|---|
US (2) | US6395467B1 (en) |
EP (1) | EP1115281B9 (en) |
AT (1) | ATE313259T1 (en) |
AU (2) | AU6499299A (en) |
CA (2) | CA2345018A1 (en) |
DE (1) | DE69929071T2 (en) |
WO (2) | WO2000016618A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001078505A1 (en) * | 2000-04-17 | 2001-10-25 | Organ Recovery Systems, Inc. | Cyclohexanediol cryoprotectant compounds |
DE10061968A1 (en) * | 2000-12-13 | 2002-06-20 | Friedrich Hoffmann | Vitrification of cornea, employs tissues of rear cornea lamellae including the stroma, Descemet membrane and endothelium |
CN108669070A (en) * | 2018-05-26 | 2018-10-19 | 温州医科大学 | A kind of cryopreservative solution and its application method of plant tissue and cell |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6312452B1 (en) | 1998-01-23 | 2001-11-06 | Innercool Therapies, Inc. | Selective organ cooling catheter with guidewire apparatus and temperature-monitoring device |
US6685732B2 (en) | 1998-03-31 | 2004-02-03 | Innercool Therapies, Inc. | Method and device for performing cooling- or cryo-therapies for, e.g., angioplasty with reduced restenosis or pulmonary vein cell necrosis to inhibit atrial fibrillation employing microporous balloon |
US6602276B2 (en) | 1998-03-31 | 2003-08-05 | Innercool Therapies, Inc. | Method and device for performing cooling- or cryo-therapies for, e.g., angioplasty with reduced restenosis or pulmonary vein cell necrosis to inhibit atrial fibrillation |
US6905494B2 (en) | 1998-03-31 | 2005-06-14 | Innercool Therapies, Inc. | Method and device for performing cooling- or cryo-therapies for, e.g., angioplasty with reduced restenosis or pulmonary vein cell necrosis to inhibit atrial fibrillation employing tissue protection |
US7291144B2 (en) | 1998-03-31 | 2007-11-06 | Innercool Therapies, Inc. | Method and device for performing cooling- or cryo-therapies for, e.g., angioplasty with reduced restenosis or pulmonary vein cell necrosis to inhibit atrial fibrillation |
US6869757B2 (en) | 2000-07-31 | 2005-03-22 | 21St Century Medicine, Inc. | Advantageous carrier solution for vitrifiable concentrations of cryoprotectants, and compatible cryoprotectant mixtures |
US20070048726A1 (en) * | 2000-01-14 | 2007-03-01 | Biolife Solutions, Inc. | Methods and Compositions for the Control of Molecular-Based Cell Death During Preservation of Cells, Tissues or Organs in a Gel-Like State |
US7250292B2 (en) * | 2000-01-26 | 2007-07-31 | 21St Century Medicine | Hypertonic reduction of chilling injury |
US6681581B2 (en) * | 2001-11-20 | 2004-01-27 | Supachill Technologies Pty. Ltd. | Pre-conditioned solute for use in cryogenic processes |
US7270946B2 (en) * | 2002-10-04 | 2007-09-18 | Organ Recovery Systems, Inc. | Method for treatment of cellular materials with sugars prior to preservation |
US7169321B2 (en) * | 2002-10-28 | 2007-01-30 | Battelle Memorial Institute | Biobased deicing/anti-icing fluids |
US7105105B2 (en) * | 2002-10-28 | 2006-09-12 | Battelle Memorial Institute | Deicing/anti-icing fluids |
US6921633B2 (en) * | 2002-11-18 | 2005-07-26 | Biolife Solutions Incorporated | Methods and compositions for the preservation of cells, tissues or organs in the vitreous state |
ES2265305B1 (en) * | 2003-01-10 | 2008-06-16 | CRYOPROTECTORS & BIOTECHNOLOGIES, S.L. | Plants and fruit trees aqueous cryoprotectant composition includes polyols, antioxidant emulsion and phosphate diluted in water |
US7011767B2 (en) * | 2003-01-10 | 2006-03-14 | Ppg Industries Ohio, Inc. | Liquid pigment dispersion and curative agents |
WO2005110083A1 (en) * | 2004-02-17 | 2005-11-24 | Cryoprotectors & Biotechnologies, S.L. | Aqueous cryoprotective composition and application method thereof |
ES2571340T3 (en) * | 2003-09-16 | 2016-05-24 | 21St Century Medicine Inc | Methods and compositions for organ cryopreservation |
JP2005126533A (en) * | 2003-10-22 | 2005-05-19 | Nippon Shokubai Co Ltd | Ice crystal growth suppressing agent, ice crystal growth onset temperature lowering agent, and water coagulation controlling agent |
DE602004024329D1 (en) * | 2003-12-02 | 2010-01-07 | Ciba Spec Chem Water Treat Ltd | PREPARATION OF AMIDES |
WO2005061088A1 (en) * | 2003-12-22 | 2005-07-07 | Finlay Warren H | Powder formation by atmospheric spray-freeze drying |
DE102006001335B4 (en) * | 2006-01-09 | 2016-08-04 | Rogers Germany Gmbh | Use of a heat-transporting medium |
US9538745B2 (en) * | 2006-04-14 | 2017-01-10 | The General Hospital Corporation | Methods for the cryopreservation of cells |
WO2007127924A2 (en) | 2006-04-28 | 2007-11-08 | Zeltiq Aesthetics, Inc. | Cryoprotectant for use with a treatment device for improved cooling of subcutaneous lipid-rich cells |
US20080101734A1 (en) * | 2006-11-01 | 2008-05-01 | Yaw-Tsan Chen | Sandbag |
EP1939265A1 (en) * | 2006-12-27 | 2008-07-02 | Services Pétroliers Schlumberger | Gas migration prevention solid additive based on crossilinked PVA micro-gel for cementing applications |
US7824725B2 (en) * | 2007-03-30 | 2010-11-02 | The Coca-Cola Company | Methods for extending the shelf life of partially solidified flowable compositions |
WO2008157555A1 (en) * | 2007-06-18 | 2008-12-24 | The University Of Alabama | Plant cryoprotectant compositions and methods of use |
ES2416209T3 (en) * | 2007-10-04 | 2013-07-30 | Petr Dejmek | Method for the conservation of a plant material |
EP2222159B1 (en) | 2007-11-20 | 2018-02-21 | Pioneer Surgical Orthobiologics, Inc. | Cryopreservation of cells using cross-linked bioactive hydrogel matrix particles |
CA2753291C (en) * | 2009-02-23 | 2017-08-15 | Cell & Tissue Systems, Inc. | Method for ice-free cryopreservation of tissue |
KR101759116B1 (en) | 2009-04-30 | 2017-07-18 | 젤티크 애스세틱스, 인코포레이티드. | Device, system and method of removing heat from subcutaneous lipid-rich cells |
US9169460B2 (en) * | 2009-05-19 | 2015-10-27 | Lifeglobal Group Llc | Flooding dish and method for changing media in the dish in the preparation of mammalian specimen culture and for cryo-preservation, freezing, vitrification and the thawing and warming of such specimens |
CN101705078B (en) * | 2009-12-02 | 2011-08-17 | 天津市东宝润滑油脂有限公司 | Formulation and preparation method for low-temperature-resistant environment-friendly automobile non-freezing solution |
ES2623127T3 (en) | 2010-02-01 | 2017-07-10 | Mikrobex | Bacteriotherapy for Clostridium difficile colitis |
US9080092B2 (en) | 2010-02-17 | 2015-07-14 | Battelle Memorial Institute | Compositions for deicing/anti-icing |
US9243176B2 (en) | 2010-02-17 | 2016-01-26 | Battelle Memorial Institute | Compositions for deicing/anti-icing |
WO2011103295A1 (en) | 2010-02-17 | 2011-08-25 | Battelle Memorial Institute | Compositions for deicing/anti-icing |
US8413462B2 (en) | 2011-03-07 | 2013-04-09 | Empire Technology Development Llc | Systems, materials, and processes for isolating nanoparticles |
MX354859B (en) * | 2011-12-14 | 2018-03-23 | Abraxis Bioscience Llc | Use of polymeric excipients for lyophilization or freezing of particles. |
EP2811827A1 (en) | 2012-02-08 | 2014-12-17 | University of Warwick | Cryopreservation of cells in absence of vitrification inducing agents |
WO2013187077A1 (en) * | 2012-06-15 | 2013-12-19 | 極東製薬工業株式会社 | Stem cell preservation medium, stem cell preservation method, and stem cell preservation system |
WO2014197562A1 (en) | 2013-06-05 | 2014-12-11 | Rebiotix, Inc. | Microbiota restoration therapy (mrt), compositions and methods of manufacture |
WO2016179379A1 (en) * | 2015-05-06 | 2016-11-10 | Zoetis Services Llc | Hydrogel formulation with mild adhesion |
GB201512303D0 (en) * | 2015-07-14 | 2015-08-19 | Kilfrost Group Plc | Heat transfer fluid composition and use |
US20170022404A1 (en) * | 2015-07-24 | 2017-01-26 | Outdoor Sports Products Llc | Method of ice formation inhibition for waterfowl decoy application |
US10905113B2 (en) | 2015-11-12 | 2021-02-02 | Regents Of The University Of Minnesota | Compositions and method for storing liquid biospecimens |
CN105860935A (en) * | 2016-01-04 | 2016-08-17 | 浙江海洋学院 | Preparation process for low-temperature phase-change nano cold storage material having bacteriostatic effect |
CN105613150B (en) * | 2016-03-10 | 2018-06-22 | 广州市绿化公司 | A kind of preparation method of ornamental plant cryoprotective agent |
US11382790B2 (en) * | 2016-05-10 | 2022-07-12 | Zeltiq Aesthetics, Inc. | Skin freezing systems for treating acne and skin conditions |
CN109788752A (en) | 2016-07-22 | 2019-05-21 | 组织测试技术有限公司 | It is saved with glycolipid enhancing cell freezing |
US11246308B2 (en) | 2016-12-20 | 2022-02-15 | Tissue Testing Technologies Llc | Ice-free preservation of large volume tissue samples for viable, functional tissue banking |
US20220125042A1 (en) * | 2017-05-17 | 2022-04-28 | Universidade Nova De Lisboa | Cryoprotectant and/or cryopreservant composition, methods and uses thereof |
GB201804233D0 (en) | 2018-03-16 | 2018-05-02 | Univ Warwick | Cryopreserving processes |
GB201804227D0 (en) * | 2018-03-16 | 2018-05-02 | Univ Warwick | Cryopreserving compositions |
JP6945487B2 (en) * | 2018-04-26 | 2021-10-06 | 三菱製紙株式会社 | Cryopreservation solution for cells or tissues |
WO2020007913A1 (en) * | 2018-07-03 | 2020-01-09 | Technische Universiteit Eindhoven | Pva as additive to cement formulations to inhibit ice recrystallization and protect against freeze-thaw damage |
JP2021532873A (en) | 2018-07-31 | 2021-12-02 | ゼルティック エステティックス インコーポレイテッド | Methods, devices, and systems to improve skin properties |
JP7261563B2 (en) * | 2018-11-02 | 2023-04-20 | 谷川油化興業株式会社 | heat exchange medium |
US11968975B2 (en) | 2019-04-30 | 2024-04-30 | Regents Of The University Of Minnesota | Compositions and methods for storing liquid biospecimens |
WO2020257322A1 (en) * | 2019-06-17 | 2020-12-24 | The Regents Of The University Of Colorado, A Body Corporate | Methods and compositions for inhibiting freeze-thaw damage in concrete and cement paste |
CL2019002299A1 (en) | 2019-08-14 | 2020-04-24 | Centro De Investig De Polimeros Avanzados | An aqueous formulation that reduces the damage caused by spring frosts in plants and their manufacturing process. |
WO2021091984A1 (en) | 2019-11-07 | 2021-05-14 | Tissue Testing Technologies Llc | Ice-free vitrification and nano-warming of large tissue samples |
AU2021365838B2 (en) | 2020-10-21 | 2024-09-19 | Tissue Testing Technologies Llc | Minimizing immunogenicity of decellularized tissues |
US20220354108A1 (en) | 2021-05-04 | 2022-11-10 | Tissue Testing Technologies Llc | Preservation methods using trehalose with other cryoprotectants being absent from the cryopreservation protocol |
WO2023086664A1 (en) | 2021-11-15 | 2023-05-19 | Tissue Testing Technologies Llc | Preservation of natural and bionengineered tissues and methods of storing and transport |
EP4433571A1 (en) | 2021-11-15 | 2024-09-25 | Tissue Testing Technologies LLC | Cassette for preservation of natural and bioengineered tissues |
CN113907067B (en) * | 2021-12-14 | 2022-04-29 | 广东乾晖生物科技有限公司 | Ice crystal-free low-temperature storage method and recovery method in supercooled state |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4559298A (en) * | 1982-11-23 | 1985-12-17 | American National Red Cross | Cryopreservation of biological materials in a non-frozen or vitreous state |
WO1996005727A1 (en) * | 1994-08-18 | 1996-02-29 | The American National Red Cross | Methods of preparing organs for cryopreservation and subsequent transplantation |
WO1996030459A1 (en) * | 1995-03-30 | 1996-10-03 | Organ, Inc. | Novel ice-controlling molecules and their applications |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3045394A (en) * | 1959-03-09 | 1962-07-24 | Dumas Milner Corp | Protection of plant life from frost damage |
US3399991A (en) * | 1964-05-05 | 1968-09-03 | Du Pont | Freeze-resistant pesticidal composition |
BE793144A (en) * | 1971-12-21 | 1973-06-21 | Hoechst Ag | PROCESS AND AGENTS ALLOWING TO INFLUENCE THE TIME |
JPS5870828A (en) * | 1981-10-23 | 1983-04-27 | Kuraray Co Ltd | Improvement in freeze stability of aqueous dispersion |
US4484409A (en) * | 1982-03-29 | 1984-11-27 | University Patents, Inc. | Prevention of freezing at moderate supercooling using synthetic polymeric ice nucleation inhibitors |
JPS59122573A (en) * | 1982-12-28 | 1984-07-16 | Nissan Motor Co Ltd | Anti-icing agent |
US5084377A (en) * | 1984-09-19 | 1992-01-28 | Larry Rowan | Cryogenic suspension method |
FR2607821B1 (en) * | 1986-12-03 | 1989-08-18 | Laforge Denys | COMPOSITION AND METHOD FOR PROTECTING SURFACES FROM GRAFFITIS |
US5047181A (en) * | 1987-04-09 | 1991-09-10 | Ceramics Process Systems Corporation | Forming of complex high performance ceramic and metallic shapes |
JPH01188311A (en) * | 1988-01-22 | 1989-07-27 | Neos Co Ltd | Cleaning agent for mold |
JPH01266212A (en) * | 1988-04-12 | 1989-10-24 | Kuraray Co Ltd | Production of high-tenacity polyvinyl alcohol fiber |
JP2865736B2 (en) * | 1989-10-16 | 1999-03-08 | 株式会社クラレ | Manufacturing method of high strength polyvinyl alcohol fiber |
WO1991010361A1 (en) | 1990-01-17 | 1991-07-25 | The Regents Of The University Of California | Composition to improve survival of biological materials |
JPH04314769A (en) * | 1991-04-11 | 1992-11-05 | Citizen Watch Co Ltd | Recording fluid |
JPH05328859A (en) * | 1992-06-02 | 1993-12-14 | Nagano Pref Gov Nokyo Chiiki Kaihatsu Kiko | Treatment method for preventing freezing and hoarfrost damage to plant and seedling subjected to frost-preventing treatment |
JPH0931448A (en) * | 1995-07-21 | 1997-02-04 | Seiki Tokyu Kogyo Kk | Preventing agent for freezing of paved road surface and prevention of freezing of paved road surface |
US5653054A (en) * | 1995-10-31 | 1997-08-05 | Frost-B-Gone, Inc. | Process for preventing frost formation on plants |
US5681385A (en) * | 1996-04-18 | 1997-10-28 | Beckenhauer; Thomas | Method for retarding efflorescence in building materials and building material that exhibits reduced efflorescence |
-
1999
- 1999-09-21 CA CA002345018A patent/CA2345018A1/en not_active Abandoned
- 1999-09-21 AU AU64992/99A patent/AU6499299A/en not_active Abandoned
- 1999-09-21 DE DE69929071T patent/DE69929071T2/en not_active Expired - Lifetime
- 1999-09-21 EP EP99954636A patent/EP1115281B9/en not_active Expired - Lifetime
- 1999-09-21 AT AT99954636T patent/ATE313259T1/en not_active IP Right Cessation
- 1999-09-21 WO PCT/US1999/021736 patent/WO2000016618A1/en active IP Right Grant
- 1999-09-21 WO PCT/US1999/021967 patent/WO2000016619A1/en active Application Filing
- 1999-09-21 US US09/400,793 patent/US6395467B1/en not_active Expired - Lifetime
- 1999-09-21 US US09/400,791 patent/US6391224B1/en not_active Expired - Lifetime
- 1999-09-21 AU AU10939/00A patent/AU1093900A/en not_active Abandoned
- 1999-09-21 CA CA2345009A patent/CA2345009C/en not_active Expired - Lifetime
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4559298A (en) * | 1982-11-23 | 1985-12-17 | American National Red Cross | Cryopreservation of biological materials in a non-frozen or vitreous state |
WO1996005727A1 (en) * | 1994-08-18 | 1996-02-29 | The American National Red Cross | Methods of preparing organs for cryopreservation and subsequent transplantation |
WO1996030459A1 (en) * | 1995-03-30 | 1996-10-03 | Organ, Inc. | Novel ice-controlling molecules and their applications |
Non-Patent Citations (2)
Title |
---|
FAHY G M ET AL: "CRYOPROTECTANT TOXICITY AND CRYOPROTECTANT TOXICITY REDUCTION: IN SEARCH OF MOLECULAR MECHANISMS", CRYOBIOLOGY,US,ACADEMIC PRESS INC, vol. 27, no. 3, 1 June 1990 (1990-06-01), pages 247 - 268, XP000607699, ISSN: 0011-2240 * |
FAHY G M ET AL: "SOME EMERGING PRINCIPLES UNDERLYING THE PHYSICAL PROPERTIES, BIOLOGICAL ACTIONS, AND UTILITY OF VITRIFICATION SOLUTIONS", CRYOBIOLOGY,US,ACADEMIC PRESS INC, vol. 24, no. 3, 1 June 1987 (1987-06-01), pages 196 - 213, XP002052410, ISSN: 0011-2240 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001078505A1 (en) * | 2000-04-17 | 2001-10-25 | Organ Recovery Systems, Inc. | Cyclohexanediol cryoprotectant compounds |
DE10061968A1 (en) * | 2000-12-13 | 2002-06-20 | Friedrich Hoffmann | Vitrification of cornea, employs tissues of rear cornea lamellae including the stroma, Descemet membrane and endothelium |
CN108669070A (en) * | 2018-05-26 | 2018-10-19 | 温州医科大学 | A kind of cryopreservative solution and its application method of plant tissue and cell |
CN108669070B (en) * | 2018-05-26 | 2021-05-25 | 温州医科大学 | Low-temperature preservation solution for plant tissues and cells and use method thereof |
Also Published As
Publication number | Publication date |
---|---|
CA2345009C (en) | 2012-02-21 |
CA2345009A1 (en) | 2000-03-30 |
EP1115281B1 (en) | 2005-12-21 |
WO2000016618A9 (en) | 2000-08-24 |
US6391224B1 (en) | 2002-05-21 |
US6395467B1 (en) | 2002-05-28 |
EP1115281A1 (en) | 2001-07-18 |
DE69929071D1 (en) | 2006-01-26 |
CA2345018A1 (en) | 2000-03-30 |
AU6499299A (en) | 2000-04-10 |
DE69929071T2 (en) | 2006-08-17 |
EP1115281B9 (en) | 2006-05-10 |
WO2000016619A1 (en) | 2000-03-30 |
ATE313259T1 (en) | 2006-01-15 |
AU1093900A (en) | 2000-04-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1115281B1 (en) | Improved cryoprotectant solutions | |
Fahy et al. | Vitrification as an approach to cryopreservation | |
EP1274302B1 (en) | Cyclohexanediol cryoprotectant compounds | |
US5952168A (en) | Method for vitrification of biological materials using alkoxylated compounds | |
Lahnsteiner et al. | Cryopreservation of spermatozoa in cyprinid fishes | |
EP0511317B1 (en) | Composition to improve survival of biological materials | |
Ali et al. | Design of vitrification solutions for the cryopreservation of embryos | |
EP1274301B1 (en) | Novel warming method of cryopreserved specimens | |
DE60103297T2 (en) | PROCEDURE FOR CRYOKON SURVIVAL OF TISSUE OR ORGANS DIFFERENT FROM BLOOD VESSELS BY VITRIFICATION | |
Bank et al. | Basic principles of cryobiology | |
US20020042131A1 (en) | Cryopreservation method using cryoprotective composition of propanediol and a vehicle solution | |
Wowk et al. | Effects of solute methoxylation on glass-forming ability and stability of vitrification solutions | |
Wowk | How cryoprotectants work | |
Fahy | Analysis of “solution effects” injury: rabbit renal cortex frozen in the presence of dimethyl sulfoxide | |
US7550255B2 (en) | Polyglycerol compositions for the protection of living systems from states of reduced metabolism | |
Brockbank et al. | Vitrification: preservation of cellular implants | |
Pegg et al. | Perfusion of rabbit kidneys with solutions containing propane-1, 2-diol | |
EP1311155B1 (en) | Carrier solution for vitrifiable concentrations of cryoprotectants, and cryoprotectant mixtures | |
CN1986780A (en) | New-type of vetrifying solution | |
Fahy et al. | Practical aspects of ice-free cryopreservation | |
Fahy | Principles of vitrification as a method of cryopreservation in reproductive biology and medicine | |
Segal et al. | Function of rabbit kidneys in vitro at normothermia following equilibration with 3.0 M Me2SO and removal by hypertonic washout at 10° C | |
Segal et al. | Kinetics of permeation and intracellular events associated with Me2SO permeation of rabbit kidneys during perfusion at 10° C | |
SCHWEIZER et al. | KIDNEY PRESERVATION FAILURE USING COMBINED COLLINS'SOLUTION AND PLASMA PERFUSION | |
Kim et al. | Influence of pre-freeze treatment and cryo-storagetemperature on the post-thaw stability of canine red blood cells cryopreserved in the presence of hydroxyethyl starch |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref document number: 2000 10939 Country of ref document: AU Kind code of ref document: A |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ CZ DE DE DK DK DM EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: C2 Designated state(s): AE AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ CZ DE DE DK DK DM EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: C2 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
COP | Corrected version of pamphlet |
Free format text: PAGES 1-27, DESCRIPTION, REPLACED BY NEW PAGES 1-27; PAGES 28-32, CLAIMS, REPLACED BY NEW PAGES 28-32; PAGES 1/10-10/10, DRAWINGS, REPLACED BY NEW PAGES 1/10-10/10; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
ENP | Entry into the national phase |
Ref document number: 2345009 Country of ref document: CA Ref document number: 2345009 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: IN/PCT/2001/00252/DE Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999954636 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1999954636 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 1999954636 Country of ref document: EP |